publicações selecionadas
- Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer
- Is there a role for diagnostic scans in the management of intermediate-risk thyroid cancer?
- Knockout do gene da calcitonina: Avaliacao fenotipica do metabolismo osseo
- LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve -mutant medullary thyroid cancer
- Burden of metastatic bone disease measured on 18F-NaF PET/computed tomography studies as a prognostic indicator in patients with medullary thyroid cancer
- Effects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study
- Is there a difference between minimal and gross extension into the strap muscles for the risk of recurrence in papillary thyroid carcinomas?
- Risk factors associated with disease-specific mortality in papillary thyroid cancer patients with distant metastases
- Genetic and clinical aspects of paediatric pheochromocytomas and paragangliomas
- LBA67 Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy
- Evidence for a Founder Effect of Exon 1 Deletion in Brazilian Patients with Paraganglioma
- Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
- RF09 | PSUN29 Evidence for a Founder Effect of SDHB Exon 1 Complete Deletion in Brazilian Patients with Paraganglioma
- How to Identify Cervical Traumatic Neuromas in the Post-operative Neck Dissection: Brief Review of the Cervical Plexus Ultrasound
- Cabozantinib versus placebo in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on histology subtypes.
- Crossed-Probes Cryoablation for the Treatment of a Sclerotic Vertebral Metastasis Abutting the Spinal Canal
- Valuable insights from real-life experiences of advanced thyroid cancer treatment with sorafenib in Latin America
- Comparison of 18F-NaF PET/CT with Other Imaging Methods in the Detection of Bone Metastases in Patients with Medullary Thyroid Cancer: a Report of a Series of 31 Cases
- Molecular profile of Hürthle cell carcinomas: recurrent mutations in the Wnt/β-catenin pathway
- Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial
- Choosing Wisely for Thyroid Conditions: Recommendations of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism
- Cabozantinib (C) versus placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on prior VEGFR-targeted therapy.
- Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma.
- 1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment
- SDHB large deletions are associated with absence of MIBG uptake in metastatic lesions of malignant paragangliomas
- Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients? Survival
